Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 1/20 | 0.65 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.65 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288869 | 1.00 | S1PR2 (0.65) | S1PR2S1PR1S1PR3KEAP1HDAC2 | |
| SCHEMBL5355498 | 0.86 | FFAR1 (0.67) | S1PR2S1PR1S1PR3FFAR1LTA4H | |
| SCHEMBL287913 | 0.86 | S1PR2 (0.66) | S1PR2S1PR1S1PR3HDAC2HDAC8 | |
| SCHEMBL27999713 | 0.86 | S1PR2 (0.66) | S1PR2S1PR1S1PR3HDAC2HDAC8 | |
| SCHEMBL4895850 | 0.84 | EPHX1 (0.56) | S1PR2S1PR1S1PR3ADRA1ASLC6A3 | |
| SCHEMBL5767750 | 0.83 | CPA3 (0.62) | KEAP1FFAR1ANPEPCPA3ENPEP | |
| SCHEMBL288473 | 0.83 | CPA3 (0.62) | KEAP1FFAR1ANPEPCPA3ENPEP | |
| SCHEMBL157500 | 0.83 | CPA3 (0.62) | KEAP1FFAR1ANPEPCPA3ENPEP | |
| SCHEMBL45498 | 0.83 | S1PR2 (0.64) | S1PR2S1PR1S1PR3KEAP1HDAC2 | |
| SCHEMBL288680 | 0.83 | S1PR2 (0.64) | S1PR2S1PR1S1PR3KEAP1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114401633-A | Pest control method, pest control agent composition, and pest control agent set | 日本曹达株式会社 | 2022-04-26 | — | — | CN | disclosed |
| EP-3826638-A1 | ELAGOLIX SODIUM COMPOSITIONS AND PROCESSES | Abbvie Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020023459-A1 | ELAGOLIX SODIUM COMPOSITIONS AND PROCESSES | ABBVIE INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| CN-104284891-B | Conformationally constrained, fully synthetic macrocyclic compounds | 波利弗尔股份公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-104284891-A | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG | 2015-01-14 | — | — | CN | disclosed |
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
| US-7253194-B2 | Compounds and inhibitors of phospholipases | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-08-07 | — | — | US | disclosed |
| US-7253194-B2 | Compounds and inhibitors of phospholipases | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-08-07 | — | — | US | disclosed |
| US-7253194-B2 | Compounds and inhibitors of phospholipases | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-08-07 | — | — | US | disclosed |
| EP-1309552-A4 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | UNIV QUEENSLAND (AU) | 2005-07-20 | — | — | EP | disclosed |
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | QUEENSLAND, THE UNIVERSITY OF (AU) | 2004-02-19 | — | — | US | disclosed |
| EP-1309552-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002008189-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | PLA2G4C, PLA2G4B, PLA2G4A | S1PR2 739/4885S1PR1 626/4885S1PR3 533/4885 |
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | S1PR2 1899/4885S1PR1 1718/4885S1PR3 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.